SIREN : 448101626
X.NOV is a French company founded 23 years ago, specialized in the sector Fabrication de matériel médico-chirurgical et dentaire. Based in HERICOURT (70400), this company of category PME shows in 2022 a revenue of 27.1 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 27 085 742 € | 24 133 205 € | 20 069 455 € | 23 608 028 € | 21 026 924 € |
| Net income | 733 975 € | 134 326 € | 900 859 € | 641 915 € | 657 817 € |
| EBITDA | -168 753 € | 220 295 € | -120 976 € | 312 868 € | 541 062 € |
| Net margin | 2.7% | 0.6% | 4.5% | 2.7% | 3.1% |
In 2022, X.NOV achieves revenue of 27.1 M€. Over the period 2018-2022, the company shows strong growth with a CAGR (compound annual growth rate) of +6.5%. Vs 2021, growth of +12% (24.1 M€ -> 27.1 M€). After deducting consumption (15.7 M€), gross margin stands at 11.4 M€, i.e. a rate of 42%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -169 k€, representing -0.6% of revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 734 k€, i.e. 2.7% of revenue. This profit can be retained or distributed to shareholders.
27 085 742 €
11 402 030 €
-168 753 €
651 936 €
733 975 €
-0.6%
The debt ratio (= Financial debt / Equity x 100) stands at 183%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 25%. The balance between equity and debt is satisfactory.
183.363%
25.288%
-2.102%
-33.254
0.9%
In 2022, the debt ratio of X.NOV (183.36) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2022, the financial autonomy of X.NOV (25.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2022, the repayment capacity of X.NOV (-33.25) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 325.34. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
325.342
-137.407
In 2022, the liquidity ratio of X.NOV (325.34) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2022, the interest coverage of X.NOV (-137.4x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 88 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 77 days. The company must finance 11 days of gap between collections and payments. Inventory turnover is 164 days (= Average inventory / Cost of goods x 360). This high level ties up cash and potentially creates obsolescence risk. Overall, WCR represents 396 days of revenue, i.e. 29.8 M€ to permanently finance. Over 2018-2022, WCR increased by +91%, requiring additional financing.
29 812 735 €
88 j
77 j
164 j
396 j
Based on 57 transactions of similar company sales
(all years),
the value of X.NOV is estimated at
4 580 015 €
(range 1 920 790€ - 9 475 268€).
The price/revenue ratio is 0.23x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 57 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare X.NOV with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de matériel médico-chirurgical et dentaire
The revenue of X.NOV in 2022 is 27.1 M€.
Yes, X.NOV generated a net profit of 734 k€ in 2022.
The headquarters of X.NOV is located in HERICOURT (70400), in the department Haute-Saone.
The tax return of X.NOV is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
X.NOV operates in the sector Fabrication de matériel médico-chirurgical et dentaire (NAF code 32.50A). See the 'Sector positioning' section above to compare the company with its competitors.